Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance (2nd stage)


Pendent de resolució

Área gestora

Oficina de Projectes Internacionals

Entidad convocante

No aplica


IMI2 - Innovative Medicines Initiative 2016

Área temática

No aplica

Tipo de ayuda

PJE_Projectes Europeus


  • Grups de Recerca (GRU)
  • Investigadors/es (INV)


Vaccines and monoclonal Antibodies (mAb) may reduce antimicrobial resistance (AMR). However, individual vaccine developers and manufacturers, as well as organisations developing mAbs and health authorities, acting alone, do not have the resources and the full expertise required to make a realistic and comparable assessment of the use of the different products on the reduction of AMR. This could instead be possible through the development of a mathematical model. For such a model to be representative of the concerns and interests of the various actors (i.e. industry and the public health sector), it should take into account the perspectives of these different actors in order to capture all relevant impacts both in terms of costs and health outcomes.

Bases de la convocatoria

Consultar bases

Web con más información

Consultar web

Fecha de publicación


Fecha de inicio de solicitudes


Fecha de presentación en la UAB

No aplica

Fecha de fin de solicitudes en el Organismo convocante


Fecha de resolución prevista



No aplica